CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
Authors
Z. and Kaplan, M.A. and Geredeli, C. and Sari, N.Y. and Ozaslan, E. and Aytekin, A. and Elkiran, E.T. and Koca, S. and Dogan, M. and Turan, N. and Yuce, O. and Sevinc, A. and Ercelep, O. and Isikdogan, A. Oruc
Publication date
1 January 2019
Publisher
Zerbinis Publications
Abstract
Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression-free survival (PFS) was 5.5 months (95% Cl: 4.1-7.8) and median overall survival (OS) was 11 months (95 % Cl: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-4.6) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as in-depedent prognostic factor for PFS in MBC patients. © 2019 Zerbinis Publications. All rights reserved
Similar works
Full text
Available Versions
Manisa Celal Bayar Üniversitesi Akademik Arşiv Sistemi
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:acikerisim.mcbu.edu.tr:20....
Last time updated on 13/09/2020
Manisa Celal Bayar Üniversitesi Akademik Arşiv Sistemi
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:acikerisim.mcbu.edu.tr:20....
Last time updated on 13/09/2020